A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab
| Autor: | James Musgrave, Malia Rasa, Gretchen Foskett, Konstantine Xoinis, Rhiana Lau, Len Tanaka, Keith Abe, Bruce Shiramizu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Pediatrics
medicine.medical_specialty biology Epidemiology business.industry 030232 urology & nephrology Shiga toxin Eculizumab urologic and male genital diseases medicine.disease_cause female genital diseases and pregnancy complications Pathophysiology Complement system 03 medical and health sciences Patient population 0302 clinical medicine hemic and lymphatic diseases biology.protein medicine 030212 general & internal medicine Safety Risk Reliability and Quality business Safety Research Escherichia coli medicine.drug |
| Zdroj: | Journal of Investigative Medicine High Impact Case Reports. 5:232470961774114 |
| ISSN: | 2324-7096 |
| DOI: | 10.1177/2324709617741144 |
| Popis: | Hemolytic uremic syndrome (HUS) can be classified as typical and atypical, and the treatment recommendations currently differ between the 2 types. Eculizumab is recommended as first-line treatment for atypical HUS; however, its use in typical HUS has been controversial. We report a case of a 10-year-old male with severe neurologic impairment who was successfully treated with eculizumab, which was started 4 days after onset of neurologic symptoms. Our case supports the use of eculizumab in typical HUS with neurologic involvement, even when given later in the course, as the pathophysiology of typical HUS has been shown to involve activation of the complement pathway, similar to atypical HUS. Further studies are required to establish the efficacy and duration of eculizumab use in this patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|